ConductScience.org, home

Paper22004366

Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis.

Li L and 5 others. J Gastroenterol Hepatol, 2012. Cited by 105 papers, by iCite.

Cite this record

ConductScience Library. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. Papers, record 22004366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22004366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis.
PubMed
Journal
J Gastroenterol Hepatol
PubMed
Year
2012
PubMed
Publication types
Journal Article, Meta-Analysis, Review
PubMed
Citations, by iCite
105
iCite
Relative citation ratio, by iCite
3.27
iCite
Revised in PubMed
2022-03-21
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li LLe
2Zhang JJialin
3Liu XXiaohua
4Li XXiaohang
5Jiao BBaoping
6Kang TTieli

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Catheter AblationMajor topic
HepatectomyMajor topic
Liver NeoplasmsMajor topic
Adult
Aged
Chi-Square Distribution
Disease-Free Survival
Evidence-Based Medicine
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Odds Ratio
Risk Assessment
Risk Factors
Survival Analysis
Time Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by62

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 105 citations.

PMIDTitleJournalYearIn PapersSource
41993155Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study.Liver Cancer2026https://conductscience.org/library/papers/41993155PubMed
41706888Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/41706888PubMed
41549287Comparison of surgical resection and radiofrequency ablation for the treatment of small hepatocellular carcinoma (≤ 3 cm): an updated meta-analysis.Syst Rev2026https://conductscience.org/library/papers/41549287PubMed
41487558Prognostic Role of Mitotic Index in Hepatocellular Carcinoma: Potential Clinical Implications for Very Early Stage Disease.J Hepatocell Carcinoma2025https://conductscience.org/library/papers/41487558PubMed
41424863Verteporfin-loaded hydrogel targeting YAP-mediated MDSCs recruitment for the treatment of residual tumors after incomplete radiofrequency ablation.Theranostics2026https://conductscience.org/library/papers/41424863PubMed
41216284Margins matter: raising the bar for thermal ablation through quantitative imaging validation in COVER-ALL.Transl Gastroenterol Hepatol2025https://conductscience.org/library/papers/41216284PubMed
41063733China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver Cancer2025https://conductscience.org/library/papers/41063733PubMed
40946121Comparative Efficacy of Thermal Ablation and Surgical Resection in Patients with Colorectal Cancer Liver Metastasis: A Systematic Review and Meta-analysis.J Gastrointest Cancer2025https://conductscience.org/library/papers/40946121PubMed
40702937Real-world treatment patterns and outcomes in patients with early-stage HCC in the US treated with resection or ablation.Hepat Oncol2025https://conductscience.org/library/papers/40702937PubMed
40547962Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma.Liver Cancer2025https://conductscience.org/library/papers/40547962PubMed
40201353Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report.Front Oncol2025https://conductscience.org/library/papers/40201353PubMed
40144682Future perspectives on immunotherapy for hepatocellular carcinoma.Ther Adv Med Oncol2025https://conductscience.org/library/papers/40144682PubMed
39881557Comparison of long-term clinical outcomes between radiofrequency ablation and hepatic resection in patients with small (≤2 cm) hepatocellular carcinoma.Hepat Oncol2024https://conductscience.org/library/papers/39881557PubMed
39687037Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence.Liver Cancer2024https://conductscience.org/library/papers/39687037PubMed
39570557APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.Hepatol Int2024https://conductscience.org/library/papers/39570557PubMed
38854817Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report.J Hepatocell Carcinoma2024https://conductscience.org/library/papers/38854817PubMed
38528198Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapy.Clin J Gastroenterol2024https://conductscience.org/library/papers/38528198PubMed
38332774Risk Models for Predicting the Recurrence and Survival in Patients With Hepatocellular Carcinoma Undergoing Radio-Frequency Ablation.Clin Med Insights Oncol2024https://conductscience.org/library/papers/38332774PubMed
38326841
Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: an updated meta-analysis and meta-regression of observational studies.
World J Surg Oncol2024https://conductscience.org/library/papers/38326841PubMed
38268916Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis.Front Immunol2023https://conductscience.org/library/papers/38268916PubMed

See all 62 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22004366

GET https://conductscience.org/api/papers/v1/22004366/cited_by?page=2